| Market Cap | $253.15M-26.1% |
| Revenue (ttm) | n/a |
| Net Income | -$66.50M |
| EPS | -$1.35 |
| Shares Out | 90.09M |
| PE Ratio | n/a |
| Forward PE | -2.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 874,566 |
| Open | $2.79 |
| Previous Close | $2.91 |
| Day's Range | $2.63 - $2.88 |
| 52-Week Range | $2.44 - $5.15 |
| Beta | 0.75 |
| Analysts | Strong Buy |
| Price Target | $11.64(+314.11%) |
| Earnings Date | Nov 5, 2026 |
About SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
$SABS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SABS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SABS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SABS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SABS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SABS from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from SABS’s recent data — informational, not investment advice
What’s Behind the Score
News check: FDA Fast-Track designation and pivotal diabetes trial data drive bullish analyst commentary; Q3 results and earnings call support constructive outlook.
